581 filings
ARS
2023 FY
TENX
Tenax Therapeutics Inc
26 Apr 24
Annual report to shareholders
8:50am
DEFA14A
TENX
Tenax Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
8:42am
DEF 14A
TENX
Tenax Therapeutics Inc
Definitive proxy
26 Apr 24
8:30am
EFFECT
TENX
Tenax Therapeutics Inc
15 Apr 24
Notice of effectiveness
12:15am
EFFECT
TENX
Tenax Therapeutics Inc
15 Apr 24
Notice of effectiveness
12:15am
POS AM
juvm4m
11 Apr 24
Prospectus update (post-effective amendment)
4:59pm
POS AM
rkolx15v kt7vsd2dn
11 Apr 24
Prospectus update (post-effective amendment)
4:56pm
8-K
yctw6gwsqg0m4h9rmayi
28 Mar 24
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
8:45am
424B3
6k0os
26 Feb 24
Prospectus supplement
4:31pm
424B3
9wp48et
26 Feb 24
Prospectus supplement
4:31pm
8-K
cds1g
23 Feb 24
Other Events
4:30pm
424B3
ih6vsei7y5lyemgt2rlq
21 Feb 24
Prospectus supplement
4:32pm
424B3
hiahh0n1j hii
21 Feb 24
Prospectus supplement
4:30pm
8-K
7k8r4wu2
20 Feb 24
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
8:33am
424B3
m4pn1bc9xuq9c
13 Feb 24
Prospectus supplement
4:32pm
8-K
awp36abl3qn59fwo
12 Feb 24
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
4:46pm
424B4
h7mlg2xya c2fizr9af
9 Feb 24
Prospectus supplement with pricing info
5:00pm
424B3
v46f2tad56f
8 Feb 24
Prospectus supplement
4:51pm
EFFECT
rf4 3vnxr
8 Feb 24
Notice of effectiveness
12:15am